This study is testing new drugs named **trevogrumab** and **garetosmab** along with another drug called **semaglutide** (Wegovy®). The study has two parts. In Part A, researchers are checking how safe trevogrumab is in healthy adults. In Part B, they are testing trevogrumab, garetosmab, and Wegovy either alone or in combination, in adults with obesity. The main goal is to see if they are safe and help with weight and fat loss. Scientists are also interested in any side effects, how much of the drug stays in the blood, and if the body fights against the drug.

• **Duration**: Part B starts after Part A finishes.
• **Eligibility**: Adults aged 18-80 years with a BMI over 30 can join Part B.
• **Exclusions**: People with diabetes, past certain surgeries, or other specific health issues cannot join.

Note: There are more rules for who can join or not join the study.